Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC

Share :
Published: 27 Sep 2021
Views: 3471
Dr Pascale Tomasini and Dr Catherine Shu

Dr Pascale Tomasino (Hôpitaux Universitaires de Marseille) and Dr Catherine Shu (Columbia University Irving Medical Center, New York, USA) discuss the CHRYSALIS study results reported at ESMO 2021, looking at amivantamab monotherapy and amivantamab in combination with lazertinib in post-osimertinib EGFR-mutant non small cell lung cancer.

They cover the background to the study, the efficacy findings and side effect profiles. They look at what the results from the CHRYSALIS trial mean for patients with NSCLC and the future of this treatment type and setting.

Background and design of the CHRYSALIS study
Analysis of the results from the CHRYSALIS study
Future treatment options for EGFR mutant NSCLC
Infusion related reactions for amivantamab
Final comments

This programme is supported by an unrestricted educational grant from Janssen.